Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IBI188 |
Trade Name | |
Synonyms | IBI-188|IBI 188|letaplimab |
Drug Descriptions |
IBI188 (letaplimab) is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, potentially leading to phagocytosis of tumor cells, activation of cytotoxic T-cells (Blood (2022) 140 (Supplement 1): 4045-4046, NCI Drug Dictionary). |
DrugClasses | CD47 Antibody 31 |
CAS Registry Number | 2283356-07-8 |
NCIT ID | C157385 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Azacitidine + IBI188 | Azacitidine IBI188 | 0 | 0 |
IBI188 | IBI188 | 0 | 1 |